Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at zanidatamab and standard treatment for bile duct and gallbladder cancer (HERIZON-BTC-302)

Overview

Cancer types:

Bile duct cancer, Biliary tree cancers, Gallbladder cancer, Secondary cancers

Status:

Open

Phase:

Phase 3

Details

This trial is looking at adding a drug called zanidatamab to for bile duct and gallbladder cancer.

It is for people whose cancer:

  • has spread into surrounding tissues and they can’t have surgery to remove it or it has spread elsewhere in the body

  • is

You pronounce zanidatamab as zan-i-dat-a-mab.

Recruitment start: 19 July 2024

Recruitment end: 1 December 2028

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr James J Harding

Supported by

Jazz Pharmaceuticals

Last reviewed: 20 Jan 2026

CRUK internal database number: 20041

Help and support